Fierce Pharma
AUGUST 2, 2024
Adaptimmune has won accelerated FDA approval | Adaptimmune has won accelerated FDA approval for Tecelra (afami-cel), a treatment for metastatic or unresectable synovial sarcoma which becomes the first engineered cell therapy for a solid tumor and the first new treatment in the indication in more than a decade.
MedCity News
AUGUST 2, 2024
Many medtech products, very often too technical and scientific, emphasize features at the expense of processes and their interactions. While the approach to patient and treatment safety is crucial, there is a notable shift towards processes centered around patients and healthcare professionals. The post Beyond Engineering: Integrating UX for Safer and More Efficient Medical Products appeared first on MedCity News.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
AUGUST 2, 2024
As growth in Vertex's cystic fibrosis portfolio buoys the company amid the launch of gene therapy Casgevy, the company is feeling confident enough to boost its revenue outlook for the year. | As of mid-July, around 20 patients completed the first step of Casgevy treatment by having their cells collected, up from five patients during the first quarter.
MedCity News
AUGUST 2, 2024
Digital solutions are changing the way CKD is managed. Through enhanced connectivity and personalized care plans tailored to individual patient needs, digital technologies allow patients to take proactive steps in managing CKD. The post Disrupting Trajectory of Chronic Kidney Disease Mortality Rates Through Digital Health Platforms appeared first on MedCity News.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Fierce Pharma
AUGUST 2, 2024
Merck is trying to determine the reasons behind the surprise decline of Gardasil in China. Eisai and Biogen's Leqembi was rejected by European authorities amid a continued slow sales ramp. | Merck is trying to determine the reasons behind the surprise decline of Gardasil in China. Eisai and Biogen's Leqembi was rejected by European authorities amid a continued slow sales ramp.
European Pharmaceutical Review
AUGUST 2, 2024
For the first time in over a decade, there is a new treatment option for patients with synovial sarcoma, a rare soft tissue cancer. The US Food and Drug Administration (FDA) has granted accelerated approval for the cell therapy TECELRA ® (afamitresgene autoleucel) to treat adults with unresectable or metastatic forms of the disease. Adaptimmune Therapeutics highlighted that TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
Pharmaceutical Commerce
AUGUST 2, 2024
In deal that has the potential to reach $1.1 billion, Otsuka aims to grow its drug pipeline, specifically in the field of rare and autoimmune diseases.
Impetus Digital
AUGUST 2, 2024
A version of this article was previously published on PharmaPhorum. Like most people these days, I have been experimenting with various artificial intelligence (AI) tools this past year. It’s remarkable to see the progress made in the technology compared to only a few months ago and there are no signs of the progress slowing down. The pharmaceutical industry has numerous use cases for AI.
MedCity News
AUGUST 2, 2024
CMS finalized a rule this week that will boost hospitals’ inpatient payment rates by 2.9%. Hospitals groups are unhappy with this payment update, arguing that it is insufficient and will exacerbate hospitals’ financial challenges. The post Why Hospitals Are Decrying CMS’ New Inpatient Payment Rule appeared first on MedCity News.
pharmaphorum
AUGUST 2, 2024
Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on cardiovascular outcomes with the drug.
MedCity News
AUGUST 2, 2024
The FDA approved Adaptimmune Therapeutics’ Tecelra as a treatment for advanced cases of synovial sarcoma. It’s the first engineered cell therapy approved for treating a solid tumor. The post Adaptimmune’s FDA Approval Marks the First for an Engineered Cell Therapy for Solid Tumors appeared first on MedCity News.
PharmaVoice
AUGUST 2, 2024
As AI tools move from hype to a daily reality at pharma companies, here are the insights users are gaining.
PharmaTimes
AUGUST 2, 2024
Cancer is estimated to affect more than three million people living in the UK, according to Macmillan Cancer Support
Pharmaceutical Technology
AUGUST 2, 2024
AbbVie has completed its acquisition of all outstanding shares of Cerevel Therapeutics in a deal valued at $8.7bn.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
pharmaphorum
AUGUST 2, 2024
FDA clears GSK's Jemperli as first-line therapy for all endometrial cancer patients, seen as key to driving sales above the $1bn threshold
PharmaTimes
AUGUST 2, 2024
The third leading cause of cancer mortality accounts for over 700,000 deaths every year
pharmaphorum
AUGUST 2, 2024
FDA has approved Adaptimmune's Tecelra for synovial sarcoma, the first engineered T-cell therapy for solid tumours
Pharmaceutical Commerce
AUGUST 2, 2024
The latest news for pharma industry insiders.
pharmaphorum
AUGUST 2, 2024
Sonde Health has made a name for itself with the development of software that can detect illness from the sound of a patient's voice. Now, it has launched a dedicated app for tracking cognitive fitness, which it hopes may be able to spot signs of decline early.The app – Sonde Cognitive Fitness – allows users to monitor brain exertion in real-time by analysing vocal biomarkers using machine learning, an approach that is analogous to the use of fitness trackers to monitor physical and heart health
PharmExec
AUGUST 2, 2024
Approval marks the first time an immuno-oncology regimen has demonstrated a survival benefit for all adults with primary advanced or recurrent endometrial cancer, company says.
Prognos Health
AUGUST 2, 2024
Effective HCP engagement is a cornerstone of successful pharmaceutical marketing. The right information, delivered at the right moment to the right HCP with a brand eligible patient, can significantly influence treatment decisions and drive brand growth. However, many pharmaceutical marketing teams grapple with patient alert solutions that are limited in scope, accuracy, or geographic reach.
Pharmaceutical Commerce
AUGUST 2, 2024
In this part of his Pharma Commerce video interview, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, dives into the challenges of safeguarding these products, while also sharing his keys to sustaining stability in the ‘recession resistant’ healthcare industry.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmExec
AUGUST 2, 2024
In this part of her Pharmaceutical Executive video interview, Charlotte Owens, MD, FACOG, Head of Medical Affairs and Outcomes Research at Organon, discusses how she's using her in-practice experience as an OB-GYN to inform Organon's strategic approach to addressing maternal health challenges.
PharmaTech
AUGUST 2, 2024
The implementation of new quality control methods must be reported to regulators, says Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates.
Pharmaceutical Technology
AUGUST 2, 2024
In 2023, Casgevy was approved in the US to treat sickle cell disease (SCD), making it the first FDA-approved gene therapy to use CRISPR-based gene editing.
PharmExec
AUGUST 2, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Pharmaceutical Technology
AUGUST 2, 2024
Merck KGaA has concluded the acquisition of Mirus Bio for €500m ($600m), enhancing its viral vector bioprocessing capabilities.
PharmExec
AUGUST 2, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Pharmaceutical Technology
AUGUST 2, 2024
The MAGE-A4-targeted genetically modified T cell therapy is indicated for the treatment of synovial sarcoma.
PharmExec
AUGUST 2, 2024
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Expert insights. Personalized for you.
332 
Let's personalize your content